WEBCAST | Product Development
The case for amylin in obesity: Zealand’s Steensberg on The BioCentury Show
How amylin’s mechanism, tolerability and muscle preservation could make it a foundational therapy in obesity
June 27, 2025 12:02 AM UTC
Mounting clinical evidence suggests amylin agonists could supplant GLP-1 molecules as the foundational backbone of future obesity therapy, says Zealand Pharma President and CEO Adam Steensberg on The BioCentury Show.
One of the leading cardiometabolic biotechs, Zealand Pharma A/S (CSE:ZEAL) received the largest-ever upfront payment in a biotech licensing deal when it partnered petrelintide with Roche (SIX:ROG; OTCQX:RHHBY) for $1.65 billion in cash payments and up to $3.6 billion in milestones. The therapy is one of the biopharma industry’s most advanced amylin programs. ...
BCIQ Company Profiles